{"id":774,"date":"2024-04-02T21:49:27","date_gmt":"2024-04-03T04:49:27","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?page_id=774"},"modified":"2026-03-19T15:58:42","modified_gmt":"2026-03-19T22:58:42","slug":"cbt-009","status":"publish","type":"page","link":"https:\/\/cloudbreakpharma.com\/zh_hk\/pipeline\/cbt-009\/","title":{"rendered":"CBT-009"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

CBT-009<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

A unique topical formulation of atropine is being developed for the treatment of juvenile myopia.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Myopia, also known as near-sightedness, can develop and progress in children and adolescents. Myopia is believed to be caused by an increase in eye length or by a change in corneal curvature, which directs light from distant objects to focus in front of the retina leading to blurred long-distance vision. Myopia with a refractive error of 0.50 to -6.00 diopters is considered to be low to moderate in severity, while myopia exceeding -6.00 diopters is considered higher in severity. Progressive myopia can also be due to an increase in the axial length of the eyeball, which heightens the risk for retinal degenerative changes and permanent vision loss. \u00a0Myopia is a leading cause of correctable vision loss with a potential for complications that can lead to blindness. If treated early, there is a potential for preventing myopia-associated complications.
<\/span><\/p>

\u963f<\/span>\u6258\u54c1\u662f\u552f\u4e00\u88ab\u8b49\u660e\u00a0<\/span>been demonstrated to be consistently effective in slowing myopic progression.<\/span>\u00a0Currently, aqueous atropine eye drops are used in some\u00a0<\/span>\u963f\u6258\u54c1\u6c34\u6ef4\u773c\u6db2\u4f86\u6cbb\u7642\u8fd1\u8996\u60a3\u8005\uff0c<\/span>queous atropine eye drops are unstable and easily decompose into belladonna, <\/span>\u6b64\u5916\uff0c\u00a0<\/span>\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u4e0d\u7a69\u5b9a\uff0c\u5bb9\u6613\u5206\u89e3\u6210\u985b\u8304\u3001\u6258\u54c1\u9178\u7b49\u7269\u8cea\uff0c\u6975\u5927\u5f71\u97ff\u4e86\u9019\u4e9b\u6ef4\u773c\u6db2\u7684\u529f\u6548\u548c\u5b89\u5168\u6027\u3002\u00a0<\/span><\/p>

\u4f5c\u70ba\u975e\u6c34\u5291\u963f\u6258\u54c1\u6ef4\u773c\u5291\uff0cCBT-009 \u8207\u6c34\u5291\u963f\u6258\u54c1\u4e0d\u540c\u7684\u662f\uff0c\u00a0<\/span>atropine by having higher stability, being preservative-free, and having higher <\/span>\u4e26\u4e14\u5177\u6709\u66f4\u9ad8\u7684\u751f\u7269\u5229\u7528\u5ea6\u3002\u00a0\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

CBT-009 A unique topical formulation of atropine is being developed for the treatment of juvenile myopia. Myopia, also known as near-sightedness, can develop and progress in children and adolescents. Myopia is believed to be caused by an increase in eye length or by a change in corneal curvature, which directs light from distant objects to […]<\/p>\n","protected":false},"author":12,"featured_media":0,"parent":48,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-774","page","type-page","status-publish","hentry"],"yoast_head":"\nCBT-009 - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"description\" content=\"Discover the potential of CBT-009 juvenile myopia eye drops clinical trial, how it differs from aqueous atropine, and its predicted MOA\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh_hk\/pipeline\/cbt-009\/\" \/>\n<meta property=\"og:locale\" content=\"zh_HK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CBT-009 - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"Discover the potential of CBT-009 juvenile myopia eye drops clinical trial, how it differs from aqueous atropine, and its predicted MOA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh_hk\/pipeline\/cbt-009\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T22:58:42+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u9810\u8a08\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/pipeline\\\/cbt-009\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/pipeline\\\/cbt-009\\\/\",\"name\":\"CBT-009 - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"datePublished\":\"2024-04-03T04:49:27+00:00\",\"dateModified\":\"2026-03-19T22:58:42+00:00\",\"description\":\"Discover the potential of CBT-009 juvenile myopia eye drops clinical trial, how it differs from aqueous atropine, and its predicted MOA\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/pipeline\\\/cbt-009\\\/#breadcrumb\"},\"inLanguage\":\"zh-HK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/pipeline\\\/cbt-009\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/pipeline\\\/cbt-009\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CBT-009\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-HK\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CBT-009 - Cloudbreak Pharma, Inc.","description":"Discover the potential of CBT-009 juvenile myopia eye drops clinical trial, how it differs from aqueous atropine, and its predicted MOA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh_hk\/pipeline\/cbt-009\/","og_locale":"zh_HK","og_type":"article","og_title":"CBT-009 - Cloudbreak Pharma, Inc.","og_description":"Discover the potential of CBT-009 juvenile myopia eye drops clinical trial, how it differs from aqueous atropine, and its predicted MOA","og_url":"https:\/\/cloudbreakpharma.com\/zh_hk\/pipeline\/cbt-009\/","og_site_name":"Cloudbreak Pharma, Inc.","article_modified_time":"2026-03-19T22:58:42+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u9810\u8a08\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/pipeline\/cbt-009\/","url":"https:\/\/cloudbreakpharma.com\/pipeline\/cbt-009\/","name":"CBT-009 - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"datePublished":"2024-04-03T04:49:27+00:00","dateModified":"2026-03-19T22:58:42+00:00","description":"Discover the potential of CBT-009 juvenile myopia eye drops clinical trial, how it differs from aqueous atropine, and its predicted MOA","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/pipeline\/cbt-009\/#breadcrumb"},"inLanguage":"zh-HK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/pipeline\/cbt-009\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/pipeline\/cbt-009\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/cloudbreakpharma.com\/pipeline\/"},{"@type":"ListItem","position":3,"name":"CBT-009"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u91ab\u85e5\u4f7f\u6211\u5011\u80fd\u66f4\u597d\u7684\u8996\u89ba\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-HK"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/pages\/774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/comments?post=774"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/pages\/774\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/pages\/48"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/media?parent=774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}